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Abstract: Ectopic pregnancy constitutes 2% of all pregnancies. In the last decades, due to the rising 
amount of caesarean sections, new localization of ectopic pregnancy has been observed — caesarean 
scar pregnancy (CSP). Cesarean scar pregnancy is an iatrogenic disease and a life-threatening condition 
which frequency will systematically rise. Because of possible serious complications, CSP should be swift ly 
diagnosed and treated. Th e purpose of this retrospective study was to demonstrate diff erent methods 
of CSP treatment performed between 2015–2018 in the Clinic of Endocrinological Gynaecology and 
Gynaecology Jagiellonian University Medical College in Cracow. Th e clinical characteristics, diagnosis, 
various methods of treatment and clinical outcomes were analysed. Defi nitive algorithm of CSP treatment 
is still not established. Pharmacological and operative methods are approved while expectant observation 
is considered unsafe due to possible risk of complications for the patient, including death.
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Introduction
An ectopic pregnancy refers to the implantation of an embryo outside of the uterus 
and it is one of the most serious complications in early pregnancy [1]. First reports 
concerning extrauterine pregnancy stem from 10th century. However, it is several 
hundred years later, in 1604, Jean Riolan of Paris was the fi rst to report an authentic 
extrauterine, tubal pregnancy. Th e patient in the fourth month of her eighth pregnancy 
died the day aft er the onset of symptoms. Until the 19th century, ectopic pregnancy was 
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known only as a universally fatal accident [2]. In 21st century extrauterine pregnancy 
is still a signifi cant cause of morbidity and mortality among women. Ectopic pregnancy 
constitutes 2% of all pregnancies, however the number is still rising. Th e rate of ectopic 
pregnancies has increased from 0.5% in 1970 to 2% today [3].
Abnormal pregnancy localises most frequently in oviduct, precisely in the 
ampulla. Non-tubal ectopic pregnancies are implanted at sites other than the fallopian 
tube. Th ese pregnancies amount for less than 10% of all extrauterine pregnancies [4]. 
Recently, due to the rising amount of caesarean sections, new location of ectopic 
pregnancy has been observed — caesarean scar pregnancy (CSP). In CSP, the gestation 
is implanted in a previous caesarean scar [5].
Despite of the fact that CSP is the least frequent type of ectopic pregnancy, its 
number is rapidly rising. Th e fi rst time, CSP was described in 1978 [6]. Until 2001 only 
19 cases of the pregnancy located in the scar aft er caesarean section were reported [7]. 
Frequency of CSP occurrence is hard to determine. Based on 6-year observation 
period, Seow et al. determined the frequency of CSP at the level of 1: 2000 among 
patients aft er caesarean section, that equals 0.15% patients aft er caesarean section and 
6.1% of all ectopic pregnancy localisations. No correlation between CSP and age was 
revealed. Th ere was also no link between time aft er caesarean section and CSP, as 
it was observed aft er 6 months aft er caesarean section as well as aft er 12  years  [5]. 
Risk for caesarean scar implantation is not clearly correlated to the number of prior 
caesarean sections and has not been correlated to single versus double layer closure of 
the hysterotomy at the time of caesarean section [8].
Two types of CSP are recognized. Type I (endogenic) — CSP with progression 
to the cervico-isthmic space or uterine cavity. Type II (exogenic) — CSP with deep 
invasion of caesarean scar defect with progression toward the bladder and abdominal 
cavity. Th e endogenic type of CSP could result in a viable pregnancy, yet with a high 
risk of bleeding at the placental site [9]. Th e accurate cause and mechanism is not 
well understood. We know that implantation of a pregnancy within the scar of 
a previous caesarean section is diff erent from an intrauterine pregnancy with placenta 
accreta [8]. Th e pregnancy with placenta accreta is within the uterine cavity. In CSP, 
the gestation sac is wholly surrounded by myometrium and the fi brous tissue of the 
scar, quite separate from the endometrial cavity [10].
The most practical and effective technique to diagnosis CSP is transvaginal 
ultrasonography. Th e ultrasonographic criteria of CSP are: a) absence of intrauterine 
gestation and empty cervical canal with clearly visible endometrium, b) A gestational 
sac located in the anterior isthmus, surrounded by the caesarean scar tissue, separated 
from the uterine cavity, c) gestational sac with or without fetal pole in presence or 
absence of cardiac activity [11].
Clinical manifestation of the pregnancy implanted in the scar aft er caesarean 
section may vary from symptomless to sharp abdominal pain with vaginal bleeding 
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even to hypovolemic shock [12]. In analysis of 57 cases of CSP, 36.8% patients did 
not have any symptoms, while in 24.6% cases sharp abdominal pain was the main 
complaint [13, 14].
Materials and Methods
Th is is a retrospective review with data collection on 23 women with diagnosed 
CSP who were hospitalized in the Clinic of Endocrinological Gynaecology and 
Gynaecology Jagiellonian University Medical College in Cracow between 2015 and 
2018. Th e article presents treatments of patients with caesarean scar pregnancies, 
in which the fi rst-trimester diagnosis was documented by transvaginal sonography, 
and their prospectively documented clinical courses and outcomes. Standard 
anthropometric data and medical history were obtained from each subject.
Results
A total of 23 women were included in the analysis. Subjects’ mean age was 33.87 ± 3.31 
years. 10 patients underwent one caesarean section (43%), 11 patients-two caesarean 
sections (48%) and two patient — four caesarean sections (8.6%). In all the patients’ 
diagnosis were made based on ultrasound examination. In 18 patients, embryo with 
present heart rate was found. In one patient embryo without heart rate was revealed. 
In the rest of the patients gestational sack without echo of the embryo was found. 
In 43% cases, diagnosis was made in 6th week of pregnancy. Th e mean bHCG level 
on admission was 36444  mIU/ml. Th e mean gestational age was 7 weeks. Patients 
admitted to the Department were hemodynamically stable, in good general condition. 
In 9 patients (39%) vaginal bleeding of poor intensity was observed, 4 patients (17%) 
reported abdominal pain. Th e rest of the patients (43%) did not report any complaints.
One of the hospitalised patient conceived aft er in vitro fertilisation procedure 
(IVF). Th e bHCG level on admission was 86497  mIU/ml. Ultrasound examination 
revealed triplet heterotopic pregnancy: diamniotic twin pregnancy in caesarean scar 
and intrauterine, alive singleton pregnancy. Th ree gestational sacks were described, 
among them one of normal intrauterine location: GS = 22 mm, CRL = 7.7  mm, 
FHR = 130/min. Two sacks were localised in the caesarean scar area. One gestational 
sack GS = 12 mm was empty with normal decidual sign. Th e second gestational 
sack GS = 27 mm contained an embryo with CRL = 5.7 mm that equals gestational 
age of 6 weeks 2 days with present FHR = 126/min. Th e patient was classifi ed for 
selective embryo reduction. In general anaesthesia, under control of transabdominal 
ultrasound, 2.5 ml of potassium chloride (KCl) was administered to each gestational 
sack localised in caesarean scar. In consecutive ultrasound examinations stable activity 
of trophoblast in caesarean scar was found and correctly developing intrauterine 
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pregnancy was confi rmed. Around the date of delivery, the patient had a caesarean 
section. Th e operation underwent without complications and the patient delivered 
a healthy new-born.
Among hospitalised patients, the highest gestational age of abnormally implanted 
pregnancy was 14 week s. Th e patient was admitted to the hospital with abdominal pain 
in the area of caesarean scar without bleeding. Ultrasound examination revealed living 
pregnancy with FHR = 145/min, BPD = 30.4 mm that was equal 15 weeks 4 days. 
Trophoblast was localised in more than 50% in protruding caesarean scar dehiscence. 
Th e patient was classifi ed for operative treatment. Aft er opening of the abdomen and 
urine bladder preparation, the foetus in the amniotic sack with trophoblast partly 
present in the abdominal cavity, partly in caesarean scar was taken out. Uterine 
curettage was performed. Uterine muscle was sutured with double-layer stitches.
36-year old patient with diagnosed caesarean scar pregnancy, was admitted to 
the department with vaginal bleeding. Ultrasound examination revealed gestational 
sack with an echo of an embryo with CRL = 2.2 mm that equals 5 weeks 5 days 
with present FHR. During hospitalisation death of the embryo was diagnosed. Th e 
patient was administered 200 mg methotrexate systemically. Despite of the treatment, 
rise in bHCG levels was observed — from 19343 mIU/ml to 25568 mIU/ml. Under 
general anaesthesia and control of the ultrasound, the content of the uterine cavity 
was evacuated by suction. Aft er the treatment satisfying drop in bHCG level was 
observed.
37-year old patient, who had undergone four caesarean sections, was diagnosed 
with obsolete caesarean scar pregnancy. On admission she was reporting fatigue and 
vaginal spotting. b-HCG level was 42000 mIU/ml. Due to the rise of bHCG level 
during hospitalisation, decision about hysteroscopic evacuation of the pregnancy 
and electrocoagulation of the niche was made. Th e procedure was performed under 
general anaesthesia, without any complications.
In two cases, collapsing gestational sack without an embryo was observed. Both 
patients presented with vaginal bleeding. In the first patient, decrease of bHCG 
level from 480 mIU/ml to 72 mIU/ml was observed. Control ultrasound revealed 
no gestational sack in caesarean scar, therefore the patient did not require any 
intervention. In the second case, bHCG level on admission was equal 12 881 mIU/ ml, 
after two days — 16 903 mIU/ml despite no observed differences in ultrasound 
examination. Due to the rise of bHCG, the patient was classifi ed for hysteroscopic 
evacuation of caesarean pregnancy. After the procedure the bHCG level was 
7522 mIU/ml.
In a 30-year-old-patient, aft er four caesarean sections, a gestation sack with an 
embryo (CRL = 7.2 mm) without FHR was observed. A conservative treatment was 
implied. 100 mg of methotrexate was administered systemically. Aft er this procedure, 
Foley’s catheter was put into uterine isthmus for 24 hours.
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The other patients hospitalised due to caesarean pregnancy with present 
FHR were between 6th and 8th week of pregnancy. Th e highest bHCG level was 
117  210  mIU/ ml, the lowest 993 mIU/ml. In ultrasound examination highest CRL 
was equal 15.5 mm, smallest — 5.5 mm. Conservative treatment was implied. Under 
general anaesthesia, transvaginal ultrasound transducer was inserted and after 
that a  special puncture needle was placed in gestational sack. Fluid was partially 
removed by suction. Subsequently 5 ml of 10% KCl or 2 ml of 15% KCl and 50 mg 
methotrexate were administered into the sack. Aft er that, 100mg of methotrexate was 
administered systemically as a continuation of the treatment. Two patients required 
additional 200 mg of methotrexate administered systemically due to abnormal bHCG 
level aft er the procedure. In two cases, patients had to be rehospitalized because of 
vaginal bleeding with occurred about 4 and 6 weeks aft er hospitalizations ending. In 
both cases, hysteroscopy with electrocoagulation od caesarean scar was performed 
without complications.
Discussion
Defi nitive algorithm of CSP treatment is still not established. Pharmacological and 
operative methods are approved while expectant observation is considered unsafe 
due to possible risk of complications for the patient, including death [8, 13]. It was 
reported that in half of the patients with no implemented treatment uterine rupture 
was the consequence, with consequent hysterectomy [15]. It is suggested to choose 
pharmacological or operative treatment in hemodynamically stable patients with CSP 
as a fertility preserving method [13].
Pharmacological treatment options include systemic or local administration 
of methotrexate (MTX), chloride potassium, hyperosmolar glucose solution, 
prostaglandin or combination of the medications in laparoscopic assist or its direct 
injection to the gestational sack under transabdominal or transvaginal ultrasound 
control.
Numerous reviews report local or systemic methotrexate administration as 
a most effective way of treatment. Single dose of 50 mg/m2 administered i.m. 
may be safe in CSP treatment up to 8th week of pregnancy with no FHR [12]. It 
is considered that MTX treatment is eff ective when serum bHCG levels are lower 
than 5000  mIU/ ml  [13,  14]. However, some authors criticize systemic MTX 
administration as an eff ective treatment method due to the fact, that fi brous tissue 
is poorly vascularised therefore drug penetration is insuffi  cient. Th ey suggest local 
administration of MTX directly to gestational sack [16]. MTX treatment alone as fi rst 
line treatment showed low success rate [17].
As per our experience, the most eff ective and safe method of CSP treatment is 
locally administered 5 ml 10% KCl and 50 mg MTX into the gestational sack and 
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100  mg MTX systemically in CSP between 6th–8th weeks pregnancy (in our cases 
CRL <21 mm). Aft er this treatment, we observed satisfying decrease in bHCG level.
Operative methods include laparotomy, uterine artery embolization, hysteroscopy 
and curettage with gestational sack suction. Th ey may be undertaken in patients 
hemodynamically unstable or when pharmacological treatment proves ineff ective. 
Combination of pharmacological and operative treatment is also implemented to 
increase success of treatment and limit risk of complications [16].
In our case, we only once were forced to make a surgery because of acute 
abdominal pain in patient in 14th weeks pregnancy in caesarean scar.
One of the first methods used in CSP is uterine curettage with secondary 
intrauterine insertion of a Foley catheter [18]. Vo and colleagues carried out a study 
to demonstrate the effi  cacy of management for CSP up to 8 weeks’ gestation using 
ultrasound-guided Foley balloon catheter placement combined with dilation and 
curettage. In their research, the Foley balloon catheter was placed inside the uterus 
under ultrasound guidance and was left  in place for 24 h. Aft erward, the patient 
underwent ultrasound-guided dilation and curettage. Follow-up to confi rm success 
included serial blood draws to measure beta-human chorionic gonadotropin (bHCG) 
levels until a value of 0, and routine ultrasounds to confi rm absence of a gestational 
sac and no evidence of vascularity at the site of the caesarean section scar. More than 
90% their patients were successfully treated with this methods. Th ey claimed that 
these treatment is more eff ective compared to standard treatment with methotrexate 
injection [19]. We proceed in a similar way in case of embryo without FHR but in all 
incidents we administrate MTX systemically as intensifi cation of treatment.
Similar research was performed by Timor-Tritsch et al. Th e aim of them study 
was to describe the placement of a cervical ripening double-balloon catheter as 
a novel treatment in patients with caesarean scar to terminate the pregnancy and at 
the same time prevent bleeding by compressing the blood supply of the gestational 
sac. Th e authors claimed that the double balloon is a successful, minimally invasive 
and well-tolerated single treatment for caesarean scar pregnancy and does not require 
any additional invasive therapies. However, the study has to be validated on a larger 
patient population [20].
Liu et al. analysed which method is safer and more eff ective in CSP treatment. 
Between 2005–2013, 38 patients with diagnosed CSP were treated with uterine artery 
embolization and curettage, while 26 patients were given methotrexate systemically 
with consequent curettage. Based on statistical analysis of blood loss during the 
procedure, time required to normalisation of bHCG level and time of hospitalisation, 
uterine artery embolization with curettage proved as a better method of CSP 
treatment [21].
Jurcovic et al. made similar observations based on 232 cases of CSP diagnosed 
in the fi rst trimester, treated between 1997–2004. 82% of the patients were treated 
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by vacuum aspiration with ECCU under ultrasound control. 4.7% patients required 
blood transfusion due to massive bleeding, while in one case hysterectomy was 
performed due to haemorrhage. In part of the patients modifi ed Shirodkar suture was 
performed [22]. Zheng et al. in their retrospective analysis based on 43 cases of CSP 
patients report; that in 91% patients the suction curettage under ultrasound control 
was the successful treatment method. According to the authors, neither uterine scar 
thickness nor time from caesarean section had an infl uence on the outcome. Only 
CRL was statistically signifi cant. Th e method proved eff ective and safe in CRL under 
6 mm [23]. On the contrary, Feng et al. in their study based on 30 cases of CSP 
report that in 25 patients who underwent prophylactic uterine artery embolization 
with methotrexate administration and subsequent ECCU under ultrasound control, 
no complications were observed, suggesting that this method is most effi  cient and 
safe [24].
Diff erent approach was presented in another research. It reports results of CSP 
treatment with the use of hysteroscopy in patients with myometrium thickness greater 
than 3 mm. According to the authors, this method is safe, effi  cient, requires short 
hospitalisation period and preserves fertility. Hysteroscopy may deal as a diagnostic 
method to confi rm the preliminary diagnosis Due to authors operative hysteroscopy 
might be recommended as a fi rst-line treatment modality for patients with a CSP, 
especially when myometrium thickness between bladder and gestational sac is more 
than 3 mm [25]. Similar opinion have Kim and colleagues. Th e authors claimed that 
wedge resection (100%) and hysteroscopy (66.7%) were relatively safe and they were 
the most successful treatment modalities in their retrospective study [16].
Xiao et al. carried out a retrospective case-control study to compare diff rent 
methods of treatment for CSP. Th e aim of their study was to explore the optimal 
intervension for CSP. 103 patients diagnosed with CSP received 1 of the 3 treatments: 
I. local or systemic methotrexate injection and surgery (MTX + Surg), II. uterine arterial 
embolization and surgery (UAE + Surg), III. only surgery (Surg-only). Th ey compared 
their therapeutic eff ects and their follow-up results. Only, the initial bHCG levels was 
highest in the MTX + Surg group. Exept for bHCG levels, clinical characteristic of the 
groups were similar. It was found that the intraoperative hemorrhage was highest 
in the Surg-only group (16.67%), compared to the MTX + Surg group (15.38%) and 
the UAE + Surg group (0%). Th e incidence of intrauterine adhesions was highest in 
the UAE + Surg group (20%), compared to the MTX + Surg group (0%) and the Surg 
only group (0%). Th e incidence of embryo residue was highest in Surg-only group 
(21.43%). Th ey came to conclusion that MTX injection with surgery might be the 
best treatment for CSP patients [26].
Th ere are few datas about CSP without intervention. However, there are still 
reports about delayed diagnosis of CSP. Jo and colleagues described a case of 
confi rmed a CSP with a live fetus with a CRL of 4.83 cm, corresponding to 11 weeks 
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pregnancy. They had to inject 50 mg of methotrexate in the amniotic sac under 
transabdominal ultrasonographic guidance but FHR was still observed 2 days later 
so they decided to perform open laparotomy because of the possibility of massive 
bleeding [27]. In the other hand, in systematic review and meta-analysis, it was 
explored the outcomes in patients managed expectantly following the diagnosis of 
CSP. 17 studies were analyzed. It was found that CSP with FHR managed expectantly 
is associated with a high burden of maternal morbidity including severe hemorrhage, 
early uterine rupture, hysterectomy. Despite this, a significant proportion of 
pregnancies complicated by CSP may progress to, or close to, term, thus questioning 
whether termination of pregnancy should be the only therapeutic option off ered to 
these patients. Expectant management of CSP with no FHR might be a reasonable 
option in view of the low likelihood of maternal complications requiring intervention, 
although close surveillance is advisable to avoid adverse maternal outcome [28].
Conclusion
Cesarean scar pregnancy is an iatrogenic disease. Despite the fact the frequency of 
cesarean scar pregnancy increases, CSP still represents a rare but serious pregnancy 
pathology [29]. CSP is a life-threatening condition with high risk of serious 
complications, therefore should be early diagnosed and treated and it should be 
managed with respect to preserve fertility [29]. Treatment of CSP is challenging. 
Because of defi nitive consensus of CSP treatment is still not established — the type 
of treatment method depends on many factors such as size of pregnancy, presence 
or absence of uterine continuity, bHCG level, the possibility of further fertility and 
patient’s hemodynamic state and should be based on the experience of the treatment 
centre.
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